文献速递湿疹皮炎与荨麻疹

乌帕替尼治疗中重度特应性皮炎:三项随机3期试验按关键基线特征的分层分析

Upadacitinib for moderate-to-severe atopic dermatitis: Stratified analysis from three randomized phase 3 trials by key baseline characteristics.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2023-06-21

该事后分析整合Measure Up 1、Measure Up 2和AD Up三项3期试验数据,共纳入2584例随机接受乌帕替尼15 mg、30 mg或安慰剂(AD Up联合外用糖皮质激素)的中重度特应性皮炎患者,按年龄、性别、种族、体重指数、疾病严重度、体表面积、特应性共病或哮喘史及既往系统治疗或环孢素暴露分层。第16周时,无论上述基线特征如何,乌帕替尼组达到EASI-75、vIGA-AD 0/1及瘙痒改善(包括最严重瘙痒数字评分量表较基线降低≥4分和评分0/1)的患者比例均持续高于安慰剂组。

要点

  • 第16周时,各基线特征亚组中乌帕替尼的EASI-75、vIGA-AD 0/1和瘙痒改善比例均持续高于安慰剂。
  • 疗效不受年龄、性别、种族、体重指数、疾病严重度、体表面积、特应性共病或哮喘史及既往系统治疗或环孢素暴露影响。
  • 结果支持乌帕替尼作为多种中重度特应性皮炎患者的合适治疗选择。

核心结论

  • 乌帕替尼在中重度特应性皮炎各亚组患者中至第16周均显示持续高的皮肤清除率和瘙痒疗效,结果支持其作为多种患者的合适治疗选择。

研究设计与样本

  • 基于Measure Up 1、Measure Up 2和AD Up三项3期试验的事后分析,共2584例中重度特应性皮炎成人和青少年被随机分配接受每日一次口服乌帕替尼15 mg、乌帕替尼30 mg或安慰剂;AD Up研究入组患者同时接受外用糖皮质激素。
  • Measure Up 1和Measure Up 2研究的数据被整合分析。

主要发现

  • 第16周时,无论年龄、性别、种族、体重指数、特应性皮炎严重度、体表面积受累、特应性共病或哮喘史、既往系统治疗或环孢素暴露如何,乌帕替尼组达到EASI-75、vIGA-AD 0/1及瘙痒改善(包括最严重瘙痒数字评分量表较基线降低≥4分和评分0/1)的患者比例均持续高于安慰剂组。

临床怎么用

  • 原文结论认为结果支持乌帕替尼作为多种中重度特应性皮炎患者的合适治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Atopic dermatitis (AD) is a heterogeneous inflammatory skin disease with different clinical phenotypes based on factors such as age, race, comorbidities, and clinical signs and symptoms. The effect of these factors on therapeutic responses in AD has only been scarcely studied and not for upadacitinib. Currently, there is no biomarker predicting response to upadacitinib. OBJECTIVES: Evaluate the efficacy of the oral Janus kinase inhibitor upadacitinib across patient subgroups (baseline demographics, disease characteristics and prior treatment) in patients with moderate-to-severe AD. METHODS: Data from phase 3 studies (Measure Up 1, Measure Up 2 and AD Up) were utilized for this post hoc analysis. Adults and adolescents with moderate-to-severe AD were randomized to receive once daily oral upadacitinib 15 mg, upadacitinib 30 mg or placebo; patients enrolled in the AD Up study received concomitant topical corticosteroids. Data from the Measure Up 1 and Measure Up 2 studies were integrated. RESULTS: A total of 2584 patients were randomized. A consistently greater proportion of patients achieved at least 75% improvement in the Eczema Area and Severity Index, a 0 or 1 on the validated Investigator Global Assessment for Atopic Dermatitis, and improvement in itch (including an achievement of a reduction of ≥4; and score of 0/1 in Worst Pruritus Numerical Rating Scale) with upadacitinib compared with placebo at Week 16, regardless of age, sex, race, body mass index, AD severity, body surface area involvement, history of atopic comorbidities or asthma, or previous exposure to systemic therapy or cyclosporin. CONCLUSIONS: Upadacitinib had consistently high skin clearance rates and itch efficacy across subgroups of patients with moderate-to-severe AD through Week 16. These results support upadacitinib as a suitable treatment option in a variety of patients. TRIAL REGISTRATION: ClinicalTrials.gov Identifiers: NCT03569293 (Measure Up 1), NCT03607422 (Measure Up 2) and NCT03568318 (AD Up).

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Thyssen JP, Thaçi D, Bieber T, et al. Upadacitinib for moderate-to-severe atopic dermatitis: Stratified analysis from three randomized phase 3 trials by key baseline characteristics. J Eur Acad Dermatol Venereol. 2023. PMID: 37247226. doi:10.1111/jdv.19232

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。